Most mAbs, expressed in mammalian cell lines, consist of a mixture of 3-5 abundant glycoforms [5] [6] [7] [8] . Other modifications, either resulting from cellular processing or introduced by sample handling or storage, can contribute to sample complexity. These include disulfide bridges between cysteine residues, N-terminal glutamine cyclization, C-terminal lysine clipping, oxidation, deamidation, nonenzymatic glycation, sequence truncation and/or single amino acid substitutions [9] [10] [11] [12] [13] .
To enhance therapeutic potential, complexity is sometimes also intentionally further increased. For instance, an emerging field in antibody-based therapy involves mixtures of mAbs. The combination of different mAbs in a single therapeutic product with different molecular targets or mechanisms of action can result in improved pharmacological profiles compared with the use of a single mAb 14, 15 , although this evidently comes at the expense of increased product heterogeneity. Another emerging field is the use of conjugates between antibodies and smallmolecule drugs; the antibody may, for instance, be used to target the coupled toxic anticancer drug to the tumor cells 16, 17 .
The importance of quality control
For the use of mAbs as therapeutic products, it is important to characterize their composition and molecular heterogeneity in detail as each component can affect the safety and efficiency of the product. A thorough structural characterization is required not only in the development stage of the antibodies but also in the production stage to control inter-batch consistency. Such analysis also helps to distinguish biosimilars from the original product 18 . To accomplish a detailed structural characterization, a wide range of techniques are used, and chromatographic techniques and MS dominate such workflows [19] [20] [21] . In the next section, we will describe in more detail one of the emerging approaches, i.e., native MS, and highlight the unique and/or complementary features that this method brings to the analysis of therapeutic mAbs.
Native MS for the analysis of mAbs
With the progressive improvements in sensitivity, resolution and mass accuracy of mass spectrometers and the subsequent development of new MS-based methods, MS is rapidly gaining momentum in the analysis of mAbs and other protein therapeutics. The mass-spectrometric analysis of mAbs at the intact protein level is already routine in many pharmaceutical and biotechnology laboratories. It is used for antibody identification by accurate mass measurements, to assess purity, and also to profile antibody glycosylation 22 . Yet for this type of analysis, denaturing conditions are still most commonly used, often in combination with liquid chromatography. This approach, although fast and sensitive, does not preserve noncovalent interactions and native-folded structures, and occasionally biopharmaceutical products are less stable and may aggregate under the conditions that are used for LC-MS.
Native MS is a particular mass-spectrometric technique that allows the analysis of intact proteins and protein complexes under more native conditions [23] [24] [25] . The use of aqueous buffers and nano-electrospray ionization (nESI) allows the retention of noncovalent interactions and the folded native conformation, broadening the range of applications for the analysis of mAbs. Moreover, native MS has some advantages over the conventional denaturing approach even in those cases in which the retention of noncovalent interaction is not strictly necessary. Owing to the folded conformation of the protein, the resulting native mass spectrum of a mAb is characterized by a smaller charge-state envelope that simplifies the spectra and also condenses the ion signals into fewer peaks, increasing the signal-to-noise ratio (S/N).
During the last few years, we and others have described how native MS can be applied in the structural characterization of intact mAbs 18, [26] [27] [28] . Most recently, we introduced a modified Orbitrap-based mass spectrometer (Exactive Plus, ThermoFisher) to the field of native MS that enables measurements with improved mass resolving power and accuracy 29, 30 . This higher resolving power allows the identification of multiple co-occurring PTMs and other minor modifications in mAbs. As the use of such a high-resolution instrument is ideal, but not always strictly required, in this protocol we describe the procedures using two different instrumental platforms: time of flight (TOF)-based mass spectrometers, which are still more routinely used for native MS, and the recently introduced Orbitrap-based instrument (Fig. 2) . We also provide recommendations on the type of applications that can be performed on the TOF instruments, and those that require the higher resolving power attained by the Orbitrap ( Table 1) .
As already mentioned, native MS has a broad range of applications 27 , from the identification of a single mAb by accurate mass measurement to the qualitative and quantitative assessment of molecular heterogeneity. Recently, we showed how native MS can also be used for the analysis of complex mixtures of mAbs 31 . The protocol presented here can be used not only to identify and relatively quantify all mixture components but also to analyze bispecific antibodies, which in early stages of development often contain residual monospecific species. Although it is not discussed here, we believe that this protocol can be further adapted for the analysis of other mAb-based therapeutics, such as Fc-fusion proteins and peptides [32] [33] [34] , and trifunctional antibodies 35 . Other types of studies in which the native conditions have been strictly required include the analysis of dimer formation in engineered CH3 domains 36 , antibody aggregation 37 , and antibody-antigen binding 38 .
As the aforementioned types of investigations do not require a very high resolving power, both TOF-and Orbitrap-based instruments can be used equally well. In contrast, when the objective of the study focuses on small modifications, such as a variety of glycosylations and/or sequence variance, or on mixtures of mAbs with very small mass differences (<0.1% of the total mass), a higher resolving power becomes compulsory. Besides higher mass accuracy for antibody identification, the Orbitrapbased instrument facilitates the characterization of glycosylation profiles, as well as the identification of sequence truncations such as C-terminal lysine clipping or other modifications such as the N-terminal glutamine cyclization 39 . To validate the identity of these various modifications, specific enzymes such as neuraminidase (sialidase), β1,4-galactosidase, glutaminylpeptide cyclotransferase and carboxypeptidase B can be used 40, 41 . Moreover, the enhanced resolving power allows the characterization of higher-complexity mixtures of antibodies up to 15 species 42 and the qualitative and quantitative analysis of heterogeneous antibody-drug conjugates 39 .
Advantages and limitations
We argue that native MS has some clear advantages. The measurements can be done rapidly (minutes for one analysis) at high sensitivity (requiring only picomoles of mAbs) and they require a minimum in sample preparation, which make it suitable for routine high-throughput analyses. However, there are evidently also some limitations. For example, smaller mass modifications such as those caused by deamidation (+1 Da) cannot (yet) be detected. Moreover, apart from the C-terminal lysine clipping, N-terminal glutamine cyclization and glycosylation that represent well-known modifications, PTMs cannot be easily site-localized. For this type of investigation, other approaches, such as bottomup peptide mapping or top-down fragmentation, are still needed.
Although accurate qualitative and quantitative mass-spectrometric data can be gathered on the various glycan structures attached to the mAbs 39 , tandem MS and NMR are still needed to convert these masses to correct glycan structures, including the appropriate linkages in between the sugar moieties.
Experimental design
In the following section, we describe the main steps in the experimental workflow. We present, on the basis of our experience, our point of view on how it can be adapted to specific sample characteristics and to the aims of the experiments (Fig. 3) . Moreover, we indicate clearly the steps that allow a wider flexibility, giving the user the possibility of altering the protocol depending on equipment and software availability.
Deglycosylation. Sample characteristics and the goal of the experiment dictate whether it is beneficial to remove the glycans before the mass analysis of the intact mAbs. In general, whenever the antibody glycans are not the objective of the study, it is valuable to include this step in the workflow for a number of reasons. First, after deglycosylation the mass spectra will become considerably simplified. Second, the collapse of all peaks arising from different glycosylation states into a single peak leads to an increase in the S/N and thus sensitivity. Third, whenever the resolution of the instrumentation does not allow baseline separation of the different glycoforms, the deglycosylation step can be seen as a The first column describes the inherent mass resolution of the mass analyzer, which is typically only reached when measuring mono-isotopic ions, such as CsI clusters, which can thus be best used for calibration purposes. For more biologically relevant molecules such as mAbs, the experimentally observed resolving power is much lower and affected by the natural isotope envelope and incomplete desolvation, and possibly by suboptimal detection efficiency. We report here both the inherent instrumental mass resolution and the experimental resolving power as full-width at half maximum at 6,000 m/z. Furthermore, optimal analyte concentrations are given. Concentrations higher than 25 µM should be avoided, whereas spectra have been demonstrated recorded with 20 nmol of mAbs. Lower concentrations can be detected but at the cost of lower signal-to-noise ratios and robustness. Owing to the presence of the quadrupole, the Q-TOF allows ion selection and therefore it has tandem MS capabilities. The Exactive Plus Orbitrap instrument does not (yet) allow ion selection, but all ions can be fragmented in the HCD cell (AIF).
Single mAb analysis
Mixtures of mAbs analysis Depending on the sample characteristics and the goal of the experiments, the workflow can be adapted. For single mAb identification (red arrows) or characterization of mAb mixtures (blue arrows), a deglycosylation step is preferable, followed by buffer exchange and analysis with either TOF-or Orbitrap-based instruments. For mAb PTMs analysis (green arrows), the workflow starts directly with the buffer exchange, and the analysis benefits from the use of an Orbitrap-based instrument. In addition, extra experiments, in which enzymes for the cleavage of specific carbohydrate residues are used instead of PNGase F, can be performed to confirm and validate glycoform assignments (Fig. 4) .
stratagem to 'sharpen' peaks, thus contributing to more accurate mass determinations. Also, when dealing with antibody mixtures and/or antibody-drug conjugates, the deglycosylation step is also beneficial, as it reduces the likelihood of overlapping ion signals in the mass spectra. However, mixtures of lower complexity can be analyzed in the native glycosylated state with higherresolution instruments. Evidently, when the goal of the investigation is the study of antibody glycosylation, samples are directly analyzed in their native glycosylated states. However, to further confirm the assignments of glycan structures, the analysis can be repeated by treating the samples with deglycosylation enzymes that cleave specific glycan residues. For instance, the enzymes neuraminidase (sialidase) and β1,4-galactosidase can be used to assess the presence of sialic acids and free galactoses, respectively (Fig. 4) .
Buffer exchange. This is an unavoidable important step for native MS. Although it has been shown that the required buffer exchange can be performed online by size-exclusion chromatography (SEC) 26 , more commonly the analyte is directly infused into the mass spectrometer without any on-line chromatographic steps. Therefore, it is necessary to exchange the original buffer into an MS-compatible one, preferably shortly before the analysis, as samples may be less stable in the pseudo-buffers used in native MS. An aqueous ammonium acetate solution does not provide that much buffering capacity, but most proteins (and protein complexes) remain bioactive and in their native structural conformation in such a solution. There are various ways to exchange the buffer; most often centrifugal-filter concentrators are used because they allow a fast buffer exchange (1-2 h), and they provide the possibility of concentrating the sample. Alternatively, the sample can be dialyzed with the advantage of a higher recovery, at the cost of lower speed and, often, sample dilution. Regarding the molecular weight cutoff (MWCO) of the filter (or membrane), for intact mAbs any MWCO lower than 150 kDa can be used. However, it may be a good habit to use a much lower MWCO, such as 10 kDa, which allows you to assess both the purity of the sample and the presence of mAb fragments, e.g., the free light chain or dissociation of the two halves of the antibody. We suggest using a buffer of 150 mM ammonium acetate at pH 7.5. Both the ionic strength and the pH can, however, be varied without markedly affecting the analysis (ionic strength 50-200 mM; pH 6.5-8).
Native MS analysis. TOF-and Orbitrap-based mass spectrometers can be used to perform native MS (Fig. 2) . In particular for TOF instruments, both the simple ESI-TOFs as well as the more extensive hybrid Q-TOFs are suitable for the analysis of mAbs. However, it is worth bearing in mind that Q-TOF instruments used for native MS require some special instrument modifications, including a low-frequency quadrupole that allows transmission of ions at high m/z values 43, 44 . Such modifications have been implemented on dedicated instruments by the original vendor (e.g., Waters); moreover, a few dedicated companies (e.g., MSVision) now offer such options commercially on existing platforms. Similarly, the Orbitrap instrument dedicated to native MS also requires some minor adjustments. This new configuration has now (September 2013) been made commercially available. In our view, nESI is essential for native MS, for efficient volatilization of aqueous buffers and for higher sensitivity 45, 46 . Similarly for TOFs and Orbitraps, samples can be manually infused into the instrument by using gold-coated capillaries (homemade, but are also commercially available); otherwise, auto samplers for direct infusion represent an attractive alternative, especially for highthroughput analysis 47, 48 .
Data analysis. The data can be processed in various ways, depending on the structural complexity of the samples, using a few available software programs. Unfortunately, the type of instrument dictates to a large extent which software may be used for data analysis. Both qualitative and quantitative data analysis can be performed either directly from the raw spectrum or by implementing a zero-charge convolution of the data with software programs such as Protein Deconvolution (Thermo) or MaxEnt (Waters). Various tools are available for the specific data analysis of mAbs, such as BPLX or BiopharmaLynx (Waters). For glycan analysis, after the analysis of the glycosylated mAbs, additional experiments can be performed by using enzymes for the specific cleavage of glycan residues such as β1,4-galactosidase and/or neuraminidase (Fig. 7) . • proceDure Deglycosylation (optional) 1| A procedure for deglycosylation by using PNGase F is described in option A. There are also a number of enzymes available that are able to (specifically) cleave particular carbohydrate residues. Additional mass analysis can be performed by using these enzymes, instead of PNGase F, to further confirm glycan structural assignments. Deglycosylation by using neuraminidase (sialidase) and β1,4-galactosidase on intact mAbs under native conditions is described in option B (Fig. 4) . Although the first enzyme cleaves both α2,3 and α2,6 acylneuraminic acids (Neu5Ac), the latter enzyme cleaves only free β1,4-galactoses. Therefore, a mixture of the two enzymes is necessary to cleave galactoses substituted with a sialic acid (Neu5Ac).
MaterIals

REAGENTS
As discussed in the INTRODUCTION, glycosylation of mAbs at the intact protein level can be studied by native MS. To perform glycoanalysis by native MS, the deglycosylation step with PNGase F (described in option A) is initially skipped, and thus glycosylated antibodies are directly buffer exchanged, infused into the mass spectrometer and analyzed. buffer exchange • tIMInG 1-2 h 2| Rinse 10-kDa-MWCO centrifugal filters, load them with 0.5 ml of ammonium acetate, pH 7.5, and centrifuge them for ~5 min at 4 °C at 10,000g. Discard the flow-through. For a cleaner procedure, also discard the buffer left in the filter by using a gel-loading pipette tip or, if the centrifugal filter device allows it, by using an alternative method of recovery.
3|
Fill the centrifugal filters with fresh ammonium acetate, pH 7.5, and the sample. Centrifuge at 4 °C for ~10 min at 10,000g.
4|
Discard the flow-through, refill the filters with fresh ammonium acetate, pH 7.5, and centrifuge again. Repeat this step until the concentration of the initial buffer reaches the nM range (typically, five or six rounds). In the last round, concentrate the solution to (at least) ~50 µl.  pause poInt Buffer-exchanged samples can be stored at 4 °C, typically for a few weeks to months. capillary preparation • tIMInG 30 min for 25 capillaries 5| Follow the instructions of the capillary puller to pull borosilicate capillaries. For optimal spray, capillaries used for nESI must end with a 10-1-µm diameter tip 46, 49 .  pause poInt Capillaries can be kept in a Petri dish, fixed on with double-sided adhesive tape.
6|
Put the Petri dish in the coating chamber and follow the manufacturer's instructions for the coater.  crItIcal step Always handle capillaries with tweezers or gloves to keep them clean before coating, and to avoid removal of the gold after coating.  pause poInt Coated capillaries can be kept in the Petri dish for a maximum of 1 month.
sample loading • tIMInG 2-5 min 7| If needed, dilute your sample down to a concentration between 5 and 1 µM (see table 1 for optimal concentration) by using ammonium acetate buffer, pH 7.5.
8|
With the help of a syringe connected with a fused silica capillary (Fig. 5a) , load ~2 µl of sample into the capillary (Fig. 5a) .  crItIcal step Handle the capillary with care to avoid damaging the capillary tip.
9|
Place the capillary in the capillary holder; follow the steps in option A or B, depending on whether you have a TOF or an Orbitrap instrument. (a) toF instrument (i) From the back of the capillary, slide a small conductive rubber between the two parts of the capillary holder to ensure conductivity (Fig. 5b) . (ii) Place the capillary onto the stage and position it at 90° to the direction of the cone. (iii) Open the capillary by touching the side of the cone or by using the tweezers under a microscope (Fig. 5c) . (iv) Position the capillary in front of the cone (Fig. 5d) calibration • tIMInG 10-30 min 11| Perform calibration by using 25 mg/ml CsI solution according to the steps described in either option A or B below.
(a) toF instrument (i) Acquire a spectrum of CsI clusters, making sure that you cover the whole mass range that has been used during the experiments (Steps 9-11). (ii) If you are using a Waters TOF instrument, calibration can be done either before or after sample measurements.
Make a calibration file (.scl) by using csiesi.ref as reference file and apply the calibration file to all acquired spectra. (b) orbitrap instrument (i) Spray the 25 mg/ml CsI solution without acquiring. Note that for Orbitrap instruments calibration needs to be performed before sample measurements. (ii) Once you have a stable spray, start mass calibration (positive mode) making sure that you are using CsI as reference.
A mass accuracy below 2 p.p.m. is preferable.
Data processing • tIMInG 1-8 h per sample 12|
Qualitative data analysis. Calculate masses of all species present in the spectra; follow the steps in option A or B, depending on whether you have a TOF or an Orbitrap instrument. When protein sequence is known, mAb identification is done by comparing the measured masses with the expected masses.  crItIcal step When calculating expected masses from the protein sequence, do not forget to take into account protein modifications (C-terminal lysine clipping, N-terminal glutamine cyclization and so on), when they are known.  crItIcal step When you have a mixture of antibodies or different proteoforms for a single antibody, the deconvoluted spectrum should closely resemble the spectrum of a single charge state of the raw spectrum. Make sure that all deconvoluted peaks are present in the raw spectrum and, on the contrary, that the deconvoluted spectrum is not missing high abundant peaks due to too-stringent parameters and/or erroneous thresholds.
13| Quantitative data analysis. When the mAb sample consists of a mixture of different antibodies and/or proteoforms, perform a relative quantification of all different species; follow the steps in option A or B, depending on whether you have a TOF or an Orbitrap instrument. (a) toF or orbitrap (i) Use Igor Pro (or any other program that allows peak fitting) to fit raw peaks and to calculate the area under the peaks. Your input into Igor Pro will be a peak list of the spectrum. (ii) Sum areas of all most-abundant charge-state peaks for each species.
Manually calculate the relative abundance of all mAb species present in the mixture. ? troublesHootInG
Troubleshooting advice can be found in table 2.
• tIMInG
Step 1, deglycosylation PNGase F: overnight Steps 2-4, buffer exchange: 1-2 h Steps 5 and 6, capillary preparation: 30 min for 25 capillaries Steps 7-9, sample loading: 2-5 min
Step 10, spectrum acquisition: 1-5 min per sample
Step 11, calibration: 10-30 min Steps 12 and 13, data processing: 1-8 h per sample
antIcIpateD results
To illustrate the applicability of the protocols, we describe two examples of mass analysis performed on mAbs by following two, TOF-and Orbitrap-based, instrumental approaches presented in the protocol. First, we show data from a qualitative and quantitative analysis of a mAb mixture consisting of four different mAbs. Because of the particular goal of the experiment being the quantitative characteristics of the mixture, the sample was first fully deglycosylated with PNGase F and the analysis was performed using, as far as mass-resolving power is concerned, a relatively low-end ESI-TOF instrument (LCT, Waters). Figure 6a shows a native mass spectrum of the aforementioned mixture. Reliable identification of the products in the mixture is ensured by accurate mass measurements, whereas relative quantification, performed by taking peak areas averaged over all charge states into account, revealed the presence of the four species in different amounts (Fig. 6b) . The second example focuses on the glycosylation analysis at the intact protein level of an IgG1Y407E mutant, which exhibits a rather complex and extended glycosylation profile, and is mainly present as a half antibody (i.e., one light chain-heavy chain pair, 75 kDa). Because of the close similarities in mass of the various glycoforms, an Orbitrap-based instrument (Exactive Plus, ThermoFisher Scientific) was used for this analysis. Because, in this case, the glycans represented the objective of the study, no deglycosylation step was performed before the analysis (Fig. 7a) . However, to further validate The quantitative analysis is performed by calculating peak areas, averaged over all detected charge states, by using dedicated software such as Igor Pro; it directly reveals differences in the abundances of the four mAbs in the mixture.
glycan assignments, the analysis was repeated with specific deglycosylation enzymes that were used for the specific cleavage of particular carbohydrate residues from the native intact mAbs. First, the sample was incubated with a β1,4-galactosidase enzyme to cleave galactose residues. The resulting mass spectra were slightly simplified, as only the peaks corresponding to glycoforms with free galactoses disappeared from the initial spectrum obtained for the unprocessed IgG1Y407E mutant, whereas glycans bearing galactoses substituted with a sialic acid were still present in the spectrum, suggesting that the enzyme is only active on free galactoses (Fig. 7b) . Next, a second experiment was performed before mass analysis by using a neuraminidase (sialidase) enzyme to cleave all α2,3 and α2,6 sialic acids. As a result, peaks corresponding to sialylated glycoforms disappeared from the mass spectra, whereas, concomitantly, an increase of some ion signals corresponding to non-sialylated species was detected (Fig. 7c ). An additional experiment was performed in which the sample had been incubated with both enzymes simultaneously. This resulted in a largely simplified spectrum exhibiting only two main glycoforms (Fig. 7d) . Finally, the IgG1Y407E mutant sample was treated with PNGase F resulting in the removal of the entire glycan from the protein backbone. The resulting mass spectrum shows a single peak corresponding to the mass of the deglycosylated mAb (Fig. 7e) 
